Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Benzinga · 1d ago
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.